TKIs currently approved for the treatment of CML were designed to target the catalytic ATP binding site of BCR-ABL1, whose efficacy tends to be compromised due to resistance mutations. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.